probucol has been researched along with Acute Coronary Syndrome in 4 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of combined atorvastatin and probucol use on endothelial function in patients with acute coronary syndrome (ACS)." | 9.14 | [Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome]. ( Liu, L; Zhao, SP; Zheng, XY, 2009) |
| " Our aim was to assess the effects of the antioxidant succinobucol (AGI-1067) on cardiovascular outcomes in patients with recent acute coronary syndromes already managed with conventional treatments." | 9.13 | Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. ( Choi, J; Cooper, J; Klug, E; L'Allier, PL; Lewis, EF; McMurray, JJ; Pfeffer, MA; Schumi, J; Scott, R; Small, R; Tardif, JC, 2008) |
| "To evaluate the effects of combined atorvastatin and probucol use on endothelial function in patients with acute coronary syndrome (ACS)." | 5.14 | [Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome]. ( Liu, L; Zhao, SP; Zheng, XY, 2009) |
| " Our aim was to assess the effects of the antioxidant succinobucol (AGI-1067) on cardiovascular outcomes in patients with recent acute coronary syndromes already managed with conventional treatments." | 5.13 | Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. ( Choi, J; Cooper, J; Klug, E; L'Allier, PL; Lewis, EF; McMurray, JJ; Pfeffer, MA; Schumi, J; Scott, R; Small, R; Tardif, JC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, XY | 1 |
| Liu, L | 1 |
| Zhao, SP | 1 |
| Gómez, G | 1 |
| Lagakos, SW | 1 |
| Recio-Mayoral, A | 1 |
| Kaski, JC | 1 |
| McMurray, JJ | 2 |
| Horowitz, J | 1 |
| van Veldhuisen, DJ | 1 |
| Remme, WJ | 1 |
| Tardif, JC | 1 |
| Klug, E | 1 |
| Small, R | 1 |
| Schumi, J | 1 |
| Choi, J | 1 |
| Cooper, J | 1 |
| Scott, R | 1 |
| Lewis, EF | 1 |
| L'Allier, PL | 1 |
| Pfeffer, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Reduction of Vascular Inflammation and Coronary Atherosclerosis With AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease"[NCT00066898] | Phase 3 | 6,000 participants | Interventional | 2003-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for probucol and Acute Coronary Syndrome
| Article | Year |
|---|---|
[Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Ch | 2009 |
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type | 2008 |
2 other studies available for probucol and Acute Coronary Syndrome
| Article | Year |
|---|---|
Statistical considerations when using a composite endpoint for comparing treatment groups.
Topics: Acute Coronary Syndrome; AIDS Vaccines; Anti-HIV Agents; Anticholesteremic Agents; Biostatistics; En | 2013 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as | 2007 |